BioVie, Inc. Common Stock
Symbol: BIVI (NASDAQ)
1.87
▼ (-1.58%) -0.030
Company Description:
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Key Stats
- Today's Open: $1.865
- Today's High: $1.899
- Today's Low: $1.865
- Today's Volume: 699
- Yesterday Close: $1.9
- Yesterday High: $1.9399
- Yesterday Low: $1.8424
- Yesterday Volume: 101.54K
- Last Min Volume: 0
- Last Min High: $1.87
- Last Min Low: $1.87
- Last Min VWAP: $0
Company Profile
- Name: BioVie, Inc. Common Stock
- Website: https://www.bioviepharma.com
- Listed Date: 2014-01-14
- Location: CARSON CITY, NV
- Market Status: Active
- CIK Number: 0001580149
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $14.32M
- Round Lot: 100
- Outstanding Shares: 7.54M
- Asset Type: CS
RECENT FILINGS FOR BIVI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-25 | DEF 14A | View |
| 2025-08-15 | 10-K | View |
| 2025-08-13 | 4 | View |
| 2025-08-11 | 8-K | View |
| 2025-08-08 | 424B5 | View |
| 2025-08-07 | EFFECT | View |
| 2025-08-07 | CERT | View |
| 2025-08-07 | 8-A12B | View |
| 2025-08-04 | CORRESP | View |
| 2025-08-04 | CORRESP | View |
| 2025-08-04 | S-1/A | View |
| 2025-07-24 | CORRESP | View |
| 2025-07-24 | CORRESP | View |
| 2025-07-23 | 8-K | View |
| 2025-07-22 | CORRESP | View |
| 2025-07-22 | CORRESP | View |
| 2025-07-22 | S-1/A | View |
| 2025-07-11 | S-1/A | View |
| 2025-07-03 | S-1 | View |
| 2025-06-30 | SCHEDULE 13D/A | View |
Latest News on BIVI